Literature DB >> 10121317

Capital disadvantage: America's failing capital investment system.

M E Porter1.   

Abstract

The U.S. system of allocating investment capital is failing, putting American companies at a serious disadvantage and threatening the long-term growth of the nation's economy. The problem, says Michael Porter, goes beyond the usual formulation of the issue: accusations of "short-termism" by U.S. managers, ineffective corporate governance by directors, or a high cost of capital. The problem involves the external capital allocation system by which capital is provided to companies, as well as the system by which companies allocate capital internally. America's system is marked by fluid capital and a financial focus. Other countries--notably Japan and Germany--have systems with dedicated capital and a focus on corporate position. In global competition, where investment increasingly determines a company's capacity to upgrade and innovate, the U.S. system does not measure up. These conclusions come out of a two-year research project sponsored by the Harvard Business School and the Council on Competitiveness. Porter recommends five far-reaching reforms to make the U.S. system superior to Japan's and Germany's: 1. Improve the present macroeconomic environment. 2. Expand true ownership throughout the system so that directors, managers, employees, and even customers and suppliers hold positions as owners. 3. Align the goals of capital providers, corporations, directors, managers, employees, customers, suppliers, and society. 4. Improve the information used in decision making. 5. Foster more productive modes of interaction and influence among capital providers, corporations, and business units.

Mesh:

Year:  1992        PMID: 10121317

Source DB:  PubMed          Journal:  Harv Bus Rev        ISSN: 0017-8012


  2 in total

1.  CEO Overconfidence and Corporate Innovation Outcomes: Evidence From China.

Authors:  Zhongze Li; Yi Zhang
Journal:  Front Psychol       Date:  2022-02-07

2.  The Impact of Compensation Gap on Corporate Innovation: Evidence from China's Pharmaceutical Industry.

Authors:  Liping Fu; Shan Zhang; Fan Wu
Journal:  Int J Environ Res Public Health       Date:  2022-02-03       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.